OPK vs. INVA, IRWD, MNKD, LXRX, PCRX, DVAX, AVIR, VSTM, ADCT, and VNDA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), Pacira BioSciences (PCRX), Dynavax Technologies (DVAX), Atea Pharmaceuticals (AVIR), Verastem (VSTM), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
OPKO Health received 203 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.79% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
OPKO Health currently has a consensus target price of $3.17, indicating a potential upside of 139.90%. Given OPKO Health's higher probable upside, research analysts clearly believe OPKO Health is more favorable than Innoviva.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 47.3% of OPKO Health shares are held by company insiders. Comparatively, 1.4% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, OPKO Health had 10 more articles in the media than Innoviva. MarketBeat recorded 12 mentions for OPKO Health and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.51 beat OPKO Health's score of 0.27 indicating that Innoviva is being referred to more favorably in the news media.
Innoviva has a net margin of 58.21% compared to OPKO Health's net margin of -31.44%. Innoviva's return on equity of 28.94% beat OPKO Health's return on equity.
OPKO Health has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Summary
Innoviva beats OPKO Health on 9 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
